<DOC>
	<DOCNO>NCT01833663</DOCNO>
	<brief_summary>This study multi-site , randomized , open parallel-controlled clinical study . The patient inclusion criterion randomly treat Solifenacin Succinate Tablets ( 5mg/d ) Solifenacin Succinate Tablets ( 5mg/d ) + local estrogen 12 week . Before dose Week 4 , 8 12 dosing , various examination make , various index evaluate .</brief_summary>
	<brief_title>Effectiveness Safety Study Solifenacin Succinate Solifenacin Succinate + Estrogen Treat OAB Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Urination Disorders</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal woman age ≤75 . Signing ICF . Willing able correctly complete urination diary . Complications OAB ≥12 week ( include : urgent micturition , frequent urination ( ≥8 time daytime , ≥2 time night ) and/or urgent urinary incontinence ) . No dose drug kind within 14d . ≥8 urination time ( 24h ) 1d urination diary . Clinicallysignificant dysuria ( investigator ' viewpoint ) . Serious stress urinary incontinence mixed stress/urgent urinary incontinence ( mainly stress one ) confirm investigator . At ongoing intubatton intermittent selfintubatton . Evidencebased urinary tract infection chronic inflammation recent 2 week ( e.g . interstitial cystitis ) , bladder calculus , past pelvic radiotherapy , past exist pelvic malignant tumor . Uncontrolled narrowangle glaucoma , urinary/gastric retention , intestinal obstruction medical symptom forbidden anticholinergic drug investigator ' viewpoint . Nonpharmacotherapy ( include electrotherapy ) bladder training within 2 week study initiation ( study ) . Dosing diuretic drug cholinergic anticholinergic adverse reaction Known suspicious allergy Solifenacin Succinate , anticholinergic drug lactose . Clinicallysignificant symptoms inapplicable clinical study investigator ' viewpoint . Participation clinical study within 30d random group . No completion urination diary accord relevant instruction . Potentially clinically significant abnormality ( PCSA ) inapplicable clinical study investigator ' viewpoint .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Solifenacin Succinate Tablets</keyword>
	<keyword>Estrogen</keyword>
</DOC>